Recombinant Human Anti-CD64 x Human Anti-EGFR Bispecific Antibody (scIgG)  (SCIGG-H299)

Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD64 and anti-EGFR IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.

Datasheet